A Study of Alendronate Sodium Vitamin D3 Tablets on Knee Osteoarthritis

Overview

The purpose of this study is to evaluate the effect of alendronate sodium vitamin D3 tablets compared with placebo on the improvement of joint structure and joint pain in participants with knee osteoarthritis. The treatment period of this study is one year and followed-up period is 2 years. The results of knee joint MRI will be evaluated by using the WORMS score.

Full Title of Study: “The Effect of Alendronate Sodium Vitamin D3 Tablets on Knee Joint Structure and Knee Osteoarthritis Pain: A Multi-center, Randomized, Double-blind, Controlled Study.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: July 2023

Detailed Description

This is a multi-center, randomized, double-blind, placebo-controlled study This study is planned to commence after obtaining Ethics Committee approval. participants will be randomised to a one-year course of alendronate sodium vitamin D3 tablets or placebo. 1:1 double blinded randomisation will be undertaken. This study plans to enroll 60 participants and will be carried out in three domestic centers (Peking Union Medical College Hospital, Zhongshan Hospital and The Third Affiliated Hospital of Southern Medical University) with a follow-up period of 2 years. As the main goal of this exploratory study is to evaluate the effect of alendronate sodium vitamin D3 tablets compared with placebo on the improvement of joint structure and joint pain in participants with knee osteoarthritis. The primary outcome measure is WORMS score of knee joint MRI at 6 months and 12 months.

Interventions

  • Drug: alendronate sodium vitamin D3 tablets
    • once per week for one year
  • Drug: Placebo
    • once per week for one year

Arms, Groups and Cohorts

  • Experimental: alendronate sodium vitamin D3 tablets
    • participants will receive alendronate sodium vitamin D3 tablets once per week for one year.
  • Placebo Comparator: placebo
    • participants will receive a placebo tablet once per week for one year.

Clinical Trial Outcome Measures

Primary Measures

  • WORMS score of knee joint MRI
    • Time Frame: The sixth month
    • WORM score of participants at the sixth month after enrollment
  • WORMS score of knee joint MRI
    • Time Frame: The 12th month
    • WORM score of participants at the 12th month after enrollment

Secondary Measures

  • WORMS score of knee joint MRI
    • Time Frame: The 24th month
    • WORM score of patients at the 24th month after enrollment
  • Pain intensity and symptom record
    • Time Frame: The second week
    • Pain intensity and symptom record of patients at the second week after enrollment
  • Pain intensity and symptom record
    • Time Frame: The 4th week
    • Pain intensity and symptom record of patients at the 4th week after enrollment
  • Pain intensity and symptom record
    • Time Frame: The 8th week
    • Pain intensity and symptom record of patients at the 8th week after enrollment
  • Pain intensity and symptom record
    • Time Frame: The 12th week
    • Pain intensity and symptom record of patients at the 12th week after enrollment
  • Quality of life (the MOS item short from health survey,SF-36 )
    • Time Frame: The third month
    • SF-36 scale of patients at the third month after enrollment
  • Quality of life (the MOS item short from health survey,SF-36 )
    • Time Frame: The sixth month
    • SF-36 scale of patients at the sixth month after enrollment. The score is calculated from eight dimensions, with the higher the final score the better
  • Quality of life (the MOS item short from health survey,SF-36 )
    • Time Frame: The 12th month
    • SF-36 scale of patients at the 12th month after enrollment. The score is calculated from eight dimensions, with the higher the final score the better
  • bone density (lumbar spine, hip joint and knee joint)
    • Time Frame: The 12th month
    • bone density of patients at the 12th month after enrollment
  • bone density (lumbar spine, hip joint and knee joint)
    • Time Frame: The 24th month
    • bone density of patients at the 24th month after enrollment
  • Risk of knee replacement
    • Time Frame: The 12th month
    • Risk of knee replacement of patients at the 12th month after enrollment
  • Risk of knee replacement
    • Time Frame: The 24th month
    • Risk of knee replacement of patients at the 24th month after enrollment
  • Kellgren & Lawrence(KL) grading Score
    • Time Frame: The 12th month
    • KL-grading Score of patients at the 12th month after enrollment, 0 to Ⅳ, higher scores mean a worse outcome
  • Kellgren & Lawrence(KL) grading Score
    • Time Frame: The 24th month
    • KL-grading Score of patients at the 12th month after enrollment, 0 to Ⅳ, higher scores mean a worse outcome
  • Serum IL-6, TNF-a, erythrocyte sedimentation rate, C-reactive protein
    • Time Frame: The third month
    • Serum inflammatory factor of patients at the third month after enrollment, IL-6 and TNF-a were measured in pg/ml,erythrocyte sedimentation rate was measured in mm/h, C-reactive protein was measured in mg/dL.
  • Serum IL-6, TNF-a, erythrocyte sedimentation rate, C-reactive protein
    • Time Frame: The sixth month
    • Serum inflammatory factor of patients at the sixth month after enrollment, IL-6 and TNF-a were measured in pg/ml,erythrocyte sedimentation rate was measured in mm/h, C-reactive protein was measured in mg/dL.
  • Serum IL-6, TNF-a, erythrocyte sedimentation rate, C-reactive protein
    • Time Frame: The 12th month
    • Serum inflammatory factor of patients at the 12th month after enrollment, IL-6 and TNF-a were measured in pg/ml,erythrocyte sedimentation rate was measured in mm/h, C-reactive protein was measured in mg/dL.

Participating in This Clinical Trial

Inclusion Criteria

1. Patients with significant knee pain (pain score≥40mm on the 100mmVAS scale); 2. Male or female patients, between 50-75 years old; 3. MRI suggests bone marrow edema-like lesions; 4. Knee osteoarthritis (in accordance with the diagnostic criteria of American College of Rheumatology (ACR) and Chinese Orthopaedic Association); 5. Kellgren-Lawrence gradingⅠorⅡin X-ray; Exclusion Criteria:

1. Other forms of active arthritis (such as rheumatoid arthritis or other inflammatory arthritis); 2. Taken non-steroidal anti-inflammatory drugs and central analgesics (such as opioids) within two weeks; 3. Liver function ALT or AST is 1.5 times the upper limit of normal; creatinine clearance <35ml/min; 4. Pregnancy or suckling; 5. Serious heart disease, endocrine, digestive, mental, nervous system diseases or cancer; 6. Active ulcers and a history of upper gastrointestinal bleeding; 7. Esophageal motility disorders, such as esophageal tardiness or stenosis; 8. Renal dysfunction or osteomalacia; 9. Tobacco addiction (mean 10 cigarettes per day or more) or/and alcohol addiction (mean 50ml per day or more); 10. Fresh fracture in the last six months; 11. Serious illnesses and life expectancy<2 years; 12. Allergic to study drugs; 13. Used any study drug or device within 30 days before randomization or within the drug half-life (whichever is longer); 14. Failure to take medication as required; 15. Replacement surgery in the near future; 16. Contraindications to MRI scans (e.g. implanted pacemakers, metal sutures, shrapnel or iron filings in the eyes, claustrophobia, knees too large to use coils); 17. Sensitive to or unsuitable for X-ray exposure (e.g. aplastic anemia, etc); 18. Poor dental health or dental surgery in the near future.

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Peking Union Medical College Hospital
  • Collaborator
    • CSPC Ouyi Pharmaceutical Co., Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Huiming Peng, 13601276089, penghuiming@139.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.